Pfizer Abrocitinib to treat atopic dermatitis meet goals in late-stage study Garima18 May 2019 9:30 AM ISTAbrocitinib, which belongs to a class of drugs known as JAK inhibitors, which block inflammation-causing enzymes, known as Janus kinases, achieved...
Sanofi to pay Regeneron $462 million in revised immuno-oncology deal Farhat Nasim9 Jan 2019 9:15 AM ISTSanofi will pay Regeneron $462 million representing the balance of payments due under their original deal, which covers the Sanofi share of the...
New AstraZeneca, Amgen drug looks strong rival in severe asthma Ruby Khatun Khatun11 Sept 2017 10:27 AM ISTLONDON: A new kind of injectable biotech treatment for severe asthma from AstraZeneca and Amgen promises to help a much broader range of patients than...
